Eton awarded patent for ET-600 desmopressin oral solution expiring 2044; NDA filing expected Q2 2025

Eton Pharmaceuticals, Inc.

USPTO granted U.S. Patent No. 12,214,010 covering ET-600's proprietary desmopressin oral solution formulation.
Patent expires in 2044 and is expected to be listed in FDA Orange Book upon product approval.
ET-600 treats diabetes insipidus; no FDA-approved oral liquid currently available for pediatric patients.
Pivotal bioequivalence study ongoing; results expected at end of February 2025.
If positive, NDA filing with FDA anticipated by Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.